CytoDyn Inc. (CYDY)
USD 0.23
(-1.61%)
USD 0.23
(-1.61%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -49.84 Million USD | 37.56% |
| 2023 | -79.82 Million USD | 72.3% |
| 2022 | -288.16 Million USD | -65.59% |
| 2021 | -174.01 Million USD | -22.74% |
| 2020 | -141.78 Million USD | -152.34% |
| 2019 | -56.18 Million USD | -15.95% |
| 2018 | -48.45 Million USD | -88.09% |
| 2017 | -25.76 Million USD | -0.23% |
| 2016 | -25.7 Million USD | 0.86% |
| 2015 | -25.92 Million USD | -108.56% |
| 2014 | -12.43 Million USD | -29.92% |
| 2013 | -9.56 Million USD | -27.7% |
| 2012 | -7.49 Million USD | -100.28% |
| 2011 | -3.74 Million USD | -0.11% |
| 2010 | -3.73 Million USD | -137.6% |
| 2009 | -1.57 Million USD | -31.76% |
| 2008 | -1.19 Million USD | 54.27% |
| 2007 | -2.61 Million USD | -75.21% |
| 2006 | -1.48 Million USD | -91.7% |
| 2005 | -777.08 Thousand USD | -117.33% |
| 2004 | -357.56 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -9.56 Million USD | 17.35% |
| 2024 FY | -49.84 Million USD | 37.56% |
| 2024 Q4 | -16.78 Million USD | -40.83% |
| 2024 Q1 | -11.57 Million USD | 37.91% |
| 2024 Q3 | -11.92 Million USD | -24.65% |
| 2023 Q1 | -29.59 Million USD | 73.2% |
| 2023 FY | -79.82 Million USD | 72.3% |
| 2023 Q3 | -15.87 Million USD | 41.49% |
| 2023 Q4 | -18.63 Million USD | -17.39% |
| 2023 Q2 | -27.13 Million USD | 8.31% |
| 2022 Q1 | -37.53 Million USD | 41.01% |
| 2022 FY | -288.16 Million USD | -65.59% |
| 2022 Q4 | -110.43 Million USD | -211.62% |
| 2022 Q3 | -35.43 Million USD | 11.22% |
| 2022 Q2 | -39.91 Million USD | -6.35% |
| 2021 Q4 | -63.62 Million USD | -44.64% |
| 2021 Q1 | -36.09 Million USD | 58.77% |
| 2021 Q2 | -39.13 Million USD | -8.42% |
| 2021 FY | -174.01 Million USD | -22.74% |
| 2021 Q3 | -43.98 Million USD | -12.39% |
| 2020 Q1 | -15.53 Million USD | -10.13% |
| 2020 Q3 | -35.76 Million USD | -144.03% |
| 2020 FY | -141.78 Million USD | -152.34% |
| 2020 Q4 | -87.54 Million USD | -144.77% |
| 2020 Q2 | -14.65 Million USD | 5.67% |
| 2019 Q2 | -14.3 Million USD | 0.75% |
| 2019 Q1 | -14.41 Million USD | -88.2% |
| 2019 Q3 | -12.57 Million USD | 12.1% |
| 2019 Q4 | -14.1 Million USD | -12.21% |
| 2019 FY | -56.18 Million USD | -15.95% |
| 2018 Q2 | -10.11 Million USD | 15.62% |
| 2018 FY | -48.45 Million USD | -88.09% |
| 2018 Q1 | -11.99 Million USD | -104.56% |
| 2018 Q3 | -17.95 Million USD | -77.41% |
| 2018 Q4 | -7.65 Million USD | 57.33% |
| 2017 FY | -25.76 Million USD | -0.23% |
| 2017 Q2 | -4.24 Million USD | 20.68% |
| 2017 Q3 | -8.11 Million USD | -91.16% |
| 2017 Q4 | -5.86 Million USD | 27.74% |
| 2017 Q1 | -5.35 Million USD | 16.65% |
| 2016 Q1 | -8.83 Million USD | 42.26% |
| 2016 FY | -25.7 Million USD | 0.86% |
| 2016 Q2 | -7.63 Million USD | 13.56% |
| 2016 Q4 | -6.41 Million USD | -27.19% |
| 2016 Q3 | -5.04 Million USD | 33.9% |
| 2015 Q4 | -15.29 Million USD | -462.07% |
| 2015 Q1 | -3.8 Million USD | -13.35% |
| 2015 Q3 | -2.72 Million USD | 52.99% |
| 2015 FY | -25.92 Million USD | -108.56% |
| 2015 Q2 | -5.78 Million USD | -52.18% |
| 2014 Q1 | -4.14 Million USD | -35.66% |
| 2014 Q4 | -3.35 Million USD | -2.51% |
| 2014 Q3 | -3.27 Million USD | 41.26% |
| 2014 FY | -12.43 Million USD | -29.92% |
| 2014 Q2 | -5.57 Million USD | -34.44% |
| 2013 Q4 | -3.05 Million USD | -29.55% |
| 2013 FY | -9.56 Million USD | -27.7% |
| 2013 Q3 | -2.35 Million USD | -26.97% |
| 2013 Q2 | -1.85 Million USD | 34.07% |
| 2013 Q1 | -2.81 Million USD | 16.97% |
| 2012 Q1 | -1.16 Million USD | -4.91% |
| 2012 FY | -7.49 Million USD | -100.28% |
| 2012 Q4 | -3.39 Million USD | -139.38% |
| 2012 Q3 | -1.41 Million USD | 5.31% |
| 2012 Q2 | -1.49 Million USD | -28.34% |
| 2011 FY | -3.74 Million USD | -0.11% |
| 2011 Q2 | -1.05 Million USD | -78.0% |
| 2011 Q3 | -1.07 Million USD | -1.76% |
| 2011 Q4 | -1.11 Million USD | -3.42% |
| 2011 Q1 | -593.75 Thousand USD | 70.35% |
| 2010 Q4 | -2 Million USD | -179.29% |
| 2010 Q1 | -323.22 Thousand USD | -343.26% |
| 2010 Q2 | -694.61 Thousand USD | -114.9% |
| 2010 Q3 | -716.9 Thousand USD | -3.21% |
| 2010 FY | -3.73 Million USD | -137.6% |
| 2009 FY | -1.57 Million USD | -31.76% |
| 2009 Q1 | -558.75 Thousand USD | -14.3% |
| 2009 Q3 | -283.14 Thousand USD | 56.97% |
| 2009 Q4 | -72.92 Thousand USD | 74.25% |
| 2009 Q2 | -657.98 Thousand USD | -17.76% |
| 2008 Q2 | -258.04 Thousand USD | -13.83% |
| 2008 Q3 | -220.1 Thousand USD | 14.7% |
| 2008 Q4 | -488.85 Thousand USD | -122.1% |
| 2008 FY | -1.19 Million USD | 54.27% |
| 2008 Q1 | -226.68 Thousand USD | 57.64% |
| 2007 Q4 | -535.15 Thousand USD | 4.32% |
| 2007 FY | -2.61 Million USD | -75.21% |
| 2007 Q2 | -727.65 Thousand USD | -14.06% |
| 2007 Q1 | -637.93 Thousand USD | 39.99% |
| 2007 Q3 | -559.33 Thousand USD | 23.13% |
| 2006 FY | -1.48 Million USD | -91.7% |
| 2006 Q3 | -274.03 Thousand USD | -229.37% |
| 2006 Q2 | -83.2 Thousand USD | -19.87% |
| 2006 Q1 | -69.41 Thousand USD | 13.91% |
| 2006 Q4 | -1.06 Million USD | -287.93% |
| 2005 Q2 | -123.42 Thousand USD | -2.25% |
| 2005 Q1 | -120.7 Thousand USD | 28.26% |
| 2005 FY | -777.08 Thousand USD | -117.33% |
| 2005 Q3 | -452.32 Thousand USD | -266.48% |
| 2005 Q4 | -80.62 Thousand USD | 82.18% |
| 2004 Q1 | -1828.00 USD | 0.0% |
| 2004 Q2 | -58.26 Thousand USD | -3087.58% |
| 2004 FY | -357.56 Thousand USD | 0.0% |
| 2004 Q3 | -129.24 Thousand USD | -121.8% |
| 2004 Q4 | -168.24 Thousand USD | -30.18% |
| 2003 Q1 | -3098.00 USD | 0.0% |
| 2003 Q2 | -2118.00 USD | 31.63% |
| 2003 Q3 | -1584.00 USD | 25.21% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -3632.203% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -613.764% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 194.077% |
| Nascent Biotech, Inc. | -2.08 Million USD | -2287.385% |
| Rebus Holdings, Inc. | -1.02 Million USD | -4786.373% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 176.522% |
| Qrons Inc. | -789.34 Thousand USD | -6214.207% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -7781.159% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 20.381% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -11896.033% |
| Skye Bioscience, Inc. | -37.64 Million USD | -32.398% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 33.513% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -657.91% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -18129.932% |
| SQZ Biotechnologies Company | -79.46 Million USD | 37.279% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -1623.175% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -2637.722% |
| Mesoblast Limited | -87.95 Million USD | 43.334% |
| Marizyme, Inc. | -65.34 Million USD | 23.729% |
| Genus plc | 7.9 Million USD | 730.899% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -357.604% |
| Pharming Group N.V. | -10.54 Million USD | -372.516% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -2197.017% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -1243.338% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -463.557% |
| ContraFect Corporation | -65.15 Million USD | 23.502% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -920.065% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -2785.227% |
| IMV Inc. | -36.48 Million USD | -36.604% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -518.399% |
| MultiCell Technologies, Inc. | -380.07 USD | -13113536.962% |
| ONE Bio Corp. | 8.67 Million USD | 674.429% |
| Accustem Sciences Inc. | -3.74 Million USD | -1230.364% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 3.581% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -3833.365% |
| Q BioMed Inc. | -2.05 Million USD | -2328.789% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -1235.146% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -1993.394% |
| Biomind Labs Inc. | -1.21 Million USD | -4004.44% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 16.55% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -1506.858% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -530.652% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -2456.933% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -332705.823% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -214.029% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -756.779% |
| GB Sciences, Inc. | -1.36 Million USD | -3560.266% |
| Alpha Cognition Inc. | -13.77 Million USD | -261.886% |
| HST Global, Inc. | -146.21 Thousand USD | -33988.64% |
| CSL Limited | 2.64 Billion USD | 101.886% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -2740.314% |
| Halberd Corporation | -79.67 Thousand USD | -62454.596% |
| Enzolytics Inc. | -2.17 Million USD | -2189.612% |
| Agentix Corp. | -1.37 Million USD | -3526.881% |
| Resverlogix Corp. | -3.61 Million USD | -1280.637% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -1471.559% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 83.108% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 50958.163% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 819.768% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -1154.495% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -1547.018% |
| AVAX Technologies, Inc. | -6.41 Million USD | -677.108% |
| Zenith Capital Corp. | -10.59 Million USD | -370.376% |
| Genscript Biotech Corporation | -95.47 Million USD | 47.798% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -214343.68% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -1102.165% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -82362.768% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -2385.693% |
| Kadimastem Ltd | -3.3 Million USD | -1406.955% |
| Helix BioMedix, Inc. | -1.05 Million USD | -4619.537% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -1205.08% |
| BioStem Technologies, Inc. | -8.48 Million USD | -487.541% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -11192.365% |
| LadRx Corporation | 400.44 Thousand USD | 12546.466% |
| Cell Source, Inc. | -5.32 Million USD | -836.648% |
| Regen BioPharma, Inc. | 1.02 Million USD | 4969.625% |
| Regen BioPharma, Inc. | 1.02 Million USD | 4969.625% |
| NovAccess Global Inc. | -4.76 Million USD | -945.063% |
| Affymax, Inc. | -14.42 Million USD | -245.542% |
| Itoco Inc. | -1.86 Million USD | -2566.727% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -1021.904% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -2886.279% |
| Mobile Lads Corp. | -2.26 Million USD | -2102.146% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -62963.53% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -21747.918% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -5193.623% |
| SYBLEU INC | -180.3 Thousand USD | -27542.759% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -2990.461% |
| International Stem Cell Corporation | -131 Thousand USD | -37946.565% |
| Bioxytran, Inc. | -4.28 Million USD | -1064.509% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -91735.569% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -1869.808% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | -3.68% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -2257.663% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -6282.614% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -1473.264% |
| Neutra Corp. | -233.46 Thousand USD | -21248.382% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -145.631% |
| PureTech Health plc | -65.69 Million USD | 24.135% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | -134.363% |
| IXICO plc | -1.17 Million USD | -4130.985% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -402.075% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 12.756% |
| CSL Limited | 2.64 Billion USD | 101.886% |
| Cellectis S.A. | -103.17 Million USD | 51.692% |